Antituberculosis therapy and current global guidelines

Giovanni Battista Migliori, Giovanni Sotgiu, Rosella Centis, Malgorzata Grzemska, Dennis Falzon, Haileyesus Getahun, Mario C. Raviglione

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The WHO Stop-TB Strategy has dramatically improved the control of TB worldwide. The emergence and the spread of anti-TB drug resistance can be prevented by the prescription of an effective anti-TB therapy. Drug sensitivity testing results are helpful to identify the most effective anti-TB drugs. WHO recommends to treat new TB cases for 6 months (H, R, Z, and E for 2 months, and H and R for other 4 months). WHO recommends to prescribe ART in all TB/HIV coinfected individuals (within the first 2 months after the start of the anti-TB therapy). Clinical management of adverse events due to anti-TB drugs increases the probability of treatment success.

Original languageEnglish
Title of host publicationCurrent and Emerging Diagnostics, Therapeutics and Vaccines for Tuberculosis
PublisherFuture Medicine Ltd.
Pages43-63
Number of pages21
ISBN (Print)9781780840222, 9781780841113
DOIs
Publication statusPublished - Oct 1 2011

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Antituberculosis therapy and current global guidelines'. Together they form a unique fingerprint.

Cite this